Christen Coats, OD
Optometrist · Fayetteville, ARNPI 1568812345
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 35.2% of the total. 2025 is the largest year on record at $106,779, more than ten times the $5,092 reported in 2019. Among optometrist clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $514.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$76K
- Sun Pharmaceutical Industries Inc.$52K
- Alcon$42K
- AbbVie$11K
- Harrow Eye, LLC$5K
- Dompe US, Inc.$5K
- plus $25K from 19 others
What the payments were for
- Consulting fees$59,43827%
- Speaking & faculty fees$117,80554%
- Travel & lodging$26,11312%
- Food & beverage$13,0576%
- Education$180%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 118 | $76,195 |
| Sun Pharmaceutical Industries Inc. | 71 | $51,873 |
| Alcon | 64 | $41,783 |
| AbbVie(2 entities) | 41 | $10,849 |
| Harrow Eye, LLC | 10 | $5,386 |
| Dompe US, Inc. | 6 | $5,140 |
| Novartis | 16 | $5,017 |
| Oyster Point Pharma, Inc. | 19 | $4,980 |
| Thea Pharma Inc. | 7 | $4,948 |
| Tarsus Pharmaceuticals, Inc. | 19 | $2,558 |
| Kala Pharmaceuticals, Inc. | 8 | $2,449 |
| Carl Zeiss Meditec, Inc. | 8 | $2,187 |
| Tearlab Corp | 1 | $1,000 |
| Shire North American Group Inc | 4 | $816 |
| Carl Zeiss Meditec USA, Inc. | 8 | $491 |
| Glaukos Corporation | 4 | $307 |
| Johnson & Johnson Vision Care, Inc. | 8 | $158 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $95 |
| Biotissue Holdings Inc. | 1 | $95 |
| Amgen | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Coopervision Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Sight Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$62,470
- XIIDRA$61,598
- CEQUA$50,429
- TOTAL30$18,644
- TRYPTYR$12,435
- DAILIES TOTAL1$11,969
- Precision 7$8,243
- Precision 1$6,963
- Precision7$6,731
- VEVYE$5,250
- Oxervate$5,070
- TYRVAYA$4,446
- EYSUVIS$2,398
- CIRRUS HD-OCT$2,273
- VUITY$2,157
- IYUZEH$1,652
- BLINK NUTRITEARS$1,600
- CLARUS$1,110
- ScoutPro Osmolarity System$1,000
- RESTASIS MULTIDOSE$891
How this compares
$216,467 in reported general payments places this provider in the 95th percentile of 442 optometrist providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 18 | $16,022 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,601 |
| AlrexLoteprednol Etabonate | 19 | $5,570 |
| Loteprednol Etabonate | 12 | $1,714 |
| Latanoprost | 32 | $210 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 16 | $178 |
| ErythromycinErythromycin Base | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $10,849 | $16,02218 claims |
| Bausch & Lomb Americas Inc.Miebo | $76,195 | $10,60114 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Loteprednol Etabonate | $95 | $7,28431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 optometrist providers in Arkansas.
Other optometrist in Fayetteville
- Michael McFarlandFayetteville$3K
- Annie AvilezFayetteville$3K
- Benjamin LynchFayetteville$3K
- Kaitlin SpikesFayetteville$2K
- Megan BaureisFayetteville$2K
- Jennifer StaffordFayetteville$2K
- Christopher MorrisRogers$6K
- Russell SimmonsBenton$6K
- Andrea HorneTontitown$6K
- Shelby BrogdonLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.